|1.||Rugg, Catherine A: 1 article (02/2008)|
|2.||Hollister, Beth: 1 article (02/2008)|
|3.||Adams, Mary: 1 article (02/2008)|
|4.||Gruninger, Robert H: 1 article (02/2008)|
|5.||Middleton, Steven A: 1 article (02/2008)|
|6.||Butler, Jeannene: 1 article (02/2008)|
|7.||Connolly, Peter J: 1 article (02/2008)|
|8.||Hughes, Terry V: 1 article (02/2008)|
|9.||Moreno-Mazza, Sandra: 1 article (02/2008)|
|10.||Greenberger, Lee M: 1 article (02/2008)|
02/01/2008 - "Tissue distribution studies show that JNJ-28871063 crosses the blood-brain barrier and penetrates into tumors, where it is able to accumulate to higher levels than those found in the plasma. "
02/01/2008 - "In an intracranial ErbB2-overexpressing tumor model, JNJ-28871063 extended survival relative to untreated animals. "
02/01/2008 - "These results show that JNJ-28871063 is orally bioavailable, has activity against EGFR and ErbB2-dependent tumor xenografts, and can penetrate into the brain and inhibit ErbB2-overexpressing tumor growth."
02/01/2008 - "JNJ-28871063 showed oral antitumor activity in human tumor xenograft models that overexpress EGFR and ErbB2. "
02/01/2008 - "Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors."
|1.||Heterologous Transplantation (Xenotransplantation)